Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update By Investing.com

MARSEILLE, France–( BUSINESS WIRE )–Regulatory News:

Innate Pharma SA (OTC:) (Euronext Paris: IPH; Nasdaq: IPHA)congenital or in Company), today announced that the Company will hold a conference call on Thursday, September 12, 2024, at 2 pm CEST / 8 am EDT, to provide an update on business progress during the first half of 2024.

Participants in the call are:

• Hervé Brailly, Chief Executive Officer
• Sonia Quaratino, Executive Vice President, Chief Medical Officer
• Yannis Morel, Executive Vice President, Chief Operating Officer
• Frédéric Lombard, Senior Vice President, Chief Financial Officer
• Arvind Sood, Executive Vice President, President of US Operations

Details for Virtual Events

The live webcast will be available at the link below:

https://events.q4inc.com/attendee/127231232

Participants can also participate by phone using the registration link below: https://registrations.events/direct/Q4I953384196

This information can also be found in the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company’s website for 90 days after the event.

About Innate Pharma

Innate Pharma SA is a global clinical-stage biotechnology company developing immunotherapy for cancer patients. The innovative approach aims to harness the innate immune system through therapeutic antibodies and ANKET ® (Antibody based NK cell Enggar Therapeutics) proprietary platform.

Innate’s portfolio includes the lead proprietary program lacutamab, developed in the form of cutaneous T-cell lymphoma and peripheral T-cell lymphoma, monalizumab developed with AstraZeneca (NASDAQ:) in non-small cell lung cancer, as well as the ANKET ® multi-specific NK cell involvement cell to deal with different types of tumors.

Innate Pharma is a trusted partner for biopharmaceutical companies such as Sanofi (NASDAQ:) and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with US offices in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about the company Innate Pharma, Inc

Disclaimer regarding forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including believe, potential, expect and will and similar expressions, are intended to identify forward-looking prospects. statement. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to many risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among others, uncertainties inherent in research and development, including those related to the safety, progress and results of clinical trials and preclinical studies conducted and planned, reviewed and approved by regulatory authorities for its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to finance its development. For an additional discussion of the risks and uncertainties that may cause the actual results, financial situation, performance or achievements of the company to differ from those contained in the forward-looking statements, read the Risk Factors section (“Facteurs de Risque”) of the Universal Registration Document filed with the Authority The French Financial Market (AMF), available on the AMF website http://www.amf-france.org or on the Innate Pharma website www.innate-pharma.com, and public filings and reports filed with the Securities and Exchange Commission AS (SEC), including the Company’s Annual Report on Form 20-F for the year ending December 31, 2023, and subsequent filings and reports filed with the AMF or the SEC, or made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe for shares in Innate Pharma in any country.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20240904420893/en/

For additional information, please contact:
Investors
Innate pharmacy
Henry Wheeler
Phone: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr

Media Relations
NewCap
Arthur Rouille
Phone: +33 (0)1 44 71 00 15
innate@newcap.eu

Source: Innate Pharma SA